TY - JOUR
T1 - The influence of the prebiotic gum acacia on the intestinal microbiome composition in rats with experimental chronic kidney disease
AU - Lakshmanan, Arun Prasath
AU - Al Za'abi, Mohammed
AU - Ali, Badreldin H.
AU - Terranegra, Annalisa
N1 - Funding Information:
We acknowledge Sidra Medicine, Doha, Qatar and Sultan Qaboos University, Muscat, Oman for funding the project. We acknowledge Dr. Shana Jacob and Sidra Medicine Deep Phenotyping Core for the SCFA analysis service. Open Access funding is provided by the Qatar National Library, Doha, Qatar.
Publisher Copyright:
© 2020 The Authors
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Chronic kidney disease (CKD) is a globally common and important disease and there are evidence for a bidirectional relationship between microbiota and CKD. The aim of the study was to examine the influence of prebiotic – gum acacia (GA) on the intestinal microbiota in rats with adenine-induced CKD. Animals were randomly distributed into four equal groups (n = 6): control, adenine, GA and adenine + GA groups. CKD was induced by adenine (0.75% w/w) given in the diet daily for four weeks, and GA was administered in drinking water at a concentration of 15% w/v. The 16s rRNA analysis was performed on Illumina Miseq targeting V3-V4 region to characterize microbial composition. The abundance of Actinobacteria, Proteobacteria, Tenericutes and Verrucomicrobia bacteria was increased in adenine-induced CKD, and GA treatment successfully reversed those levels. Interestingly, alpha and beta diversity index were both reduced with GA treatment in rats with CKD. Short chain fatty acids (SCFAs) measurement and PICRUSt analysis have shown that GA treatment completely restored the depleted butyrate level and various perturbated functional pathways, respectively, in CKD rats. Taking together, our results suggest that GA supplementation has a beneficial role in treating CKD, through an increased production of butyrate, as well as its anti-inflammatory, antioxidant capacity and anti-nitrosative properties.
AB - Chronic kidney disease (CKD) is a globally common and important disease and there are evidence for a bidirectional relationship between microbiota and CKD. The aim of the study was to examine the influence of prebiotic – gum acacia (GA) on the intestinal microbiota in rats with adenine-induced CKD. Animals were randomly distributed into four equal groups (n = 6): control, adenine, GA and adenine + GA groups. CKD was induced by adenine (0.75% w/w) given in the diet daily for four weeks, and GA was administered in drinking water at a concentration of 15% w/v. The 16s rRNA analysis was performed on Illumina Miseq targeting V3-V4 region to characterize microbial composition. The abundance of Actinobacteria, Proteobacteria, Tenericutes and Verrucomicrobia bacteria was increased in adenine-induced CKD, and GA treatment successfully reversed those levels. Interestingly, alpha and beta diversity index were both reduced with GA treatment in rats with CKD. Short chain fatty acids (SCFAs) measurement and PICRUSt analysis have shown that GA treatment completely restored the depleted butyrate level and various perturbated functional pathways, respectively, in CKD rats. Taking together, our results suggest that GA supplementation has a beneficial role in treating CKD, through an increased production of butyrate, as well as its anti-inflammatory, antioxidant capacity and anti-nitrosative properties.
KW - Butyrate
KW - CHRONIC-RENAL-FAILURE
KW - Chronic kidney disease
KW - DIET
KW - FERMENTATION
KW - Gum acacia
KW - HEALTH
KW - HEMODIALYSIS
KW - INDOXYL SULFATE
KW - INFLAMMATION
KW - Intestinal microbiome
KW - PROTEIN-INTAKE
KW - THERAPY
KW - UREMIC TOXINS
UR - http://www.scopus.com/inward/record.url?scp=85095987869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095987869&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/a15a32c4-ffc3-3f96-b939-3a154e4b21fe/
U2 - 10.1016/j.biopha.2020.110992
DO - 10.1016/j.biopha.2020.110992
M3 - Article
C2 - 33202283
AN - SCOPUS:85095987869
SN - 0753-3322
VL - 133
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
M1 - 110992
ER -